Citi Maintains Buy on ProQR Therapeutics, Lowers Price Target to $33

Citi maintains ProQR Therapeutics (NASDAQ:PRQR) with a Buy and lowers the price target from $40 to $33.

Benzinga · 11/19/2019 13:20

Citi maintains ProQR Therapeutics (NASDAQ:PRQR) with a Buy and lowers the price target from $40 to $33.